{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,23]],"date-time":"2026-10-23T23:30:39Z","timestamp":1792798239224,"version":"4.5.0"},"reference-count":89,"publisher":"Deutscher Arzte-Verlag GmbH","content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":[],"DOI":"10.3238\/arztebl.m2025.0162","type":"journal-article","created":{"date-parts":[[2025,11,20]],"date-time":"2025-11-20T13:09:37Z","timestamp":1763644177000},"source":"Crossref","is-referenced-by-count":2,"title":["Pulmonary involvement in autoimmune-mediated disease"],"prefix":"10.3238","author":[{"given":"Tobias","family":"Hoffmann","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Martin","family":"Aringer","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Dirk","family":"Koschel","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Andreas","family":"Krause","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Gunter","family":"Wolf","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Alexander","family":"Pfeil","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"11437","published-online":{"date-parts":[[2025,11,28]]},"reference":[{"key":"10.3238\/arztebl.m2025.0162_ref1","doi-asserted-by":"crossref","unstructured":"Kreuter M, Behr J, Bonella F, et al.: [Consensus guideline on the interdisciplinary diagnosis of interstitial lung diseases]. Pneumologie 2023; 77: 269\u2013302","DOI":"10.1055\/a-2017-8971"},{"key":"10.3238\/arztebl.m2025.0162_ref2","doi-asserted-by":"crossref","unstructured":"Lynch DA, Sverzellati N, Travis WD, et al.: Diagnostic criteria for idiopathic pulmonary fibrosis: A fleischner society white paper. Lancet Respir Med 2018; 6: 138\u201353","DOI":"10.1016\/S2213-2600(17)30433-2"},{"key":"10.3238\/arztebl.m2025.0162_ref3","doi-asserted-by":"crossref","unstructured":"Raghu G, Remy-Jardin M, Richeldi L, et al.: Idiopathic pulmonary fibrosis (an update) and progressive pulmonary fibrosis in adults: An official ATS\/ERS\/JRS\/ALAT clinical practice guideline. Am J Respir Crit Care Med 2022; 205: e18\u2013e47","DOI":"10.1164\/rccm.202202-0399ST"},{"key":"10.3238\/arztebl.m2025.0162_ref4","doi-asserted-by":"crossref","unstructured":"Joy GM, Arbiv OA, Wong CK, et al.: Prevalence, imaging patterns and risk factors of interstitial lung disease in connective tissue disease: A systematic review and meta-analysis. Eur Respir Rev 2023; 32: 220210","DOI":"10.1183\/16000617.0210-2022"},{"key":"10.3238\/arztebl.m2025.0162_ref5","doi-asserted-by":"crossref","unstructured":"Hoffmann-Vold AM, Allanore Y, Alves M, et al.: Progressive interstitial lung disease in patients with systemic sclerosis-associated interstitial lung disease in the EUSTAR database. Ann Rheum Dis 2021; 80: 219\u201327","DOI":"10.1136\/annrheumdis-2020-217455"},{"key":"10.3238\/arztebl.m2025.0162_ref6","doi-asserted-by":"crossref","unstructured":"Tyndall AJ, Bannert B, Vonk M, et al.: Causes and risk factors for death in systemic sclerosis: A study from the EULAR Scleroderma Trials and Research (EUSTAR) database. Ann Rheum Dis 2010; 69: 1809\u201315","DOI":"10.1136\/ard.2009.114264"},{"key":"10.3238\/arztebl.m2025.0162_ref7","doi-asserted-by":"crossref","unstructured":"Raghu G, Collard HR, Egan JJ, et al.: An official ATS\/ERS\/JRS\/ALAT statement: Idiopathic pulmonary fibrosis: Evidence-based guidelines for diagnosis and management. Am J Respir Crit Care Med 2011; 183: 788\u2013824","DOI":"10.1164\/rccm.2009-040GL"},{"key":"10.3238\/arztebl.m2025.0162_ref8","doi-asserted-by":"crossref","unstructured":"Johnson SR, Bernstein EJ, Bolster MB, et al.: 2023 American College of Rheumatology (ACR)\/American College of Chest Physicians (CHEST) Guideline for the Screening and Monitoring of Interstitial Lung Disease in People with Systemic Autoimmune Rheumatic Diseases. Arthritis Care Res (Hoboken) 2024; 76: 1070\u201382","DOI":"10.1002\/acr.25347"},{"key":"10.3238\/arztebl.m2025.0162_ref9","doi-asserted-by":"crossref","unstructured":"Matteson EL, Kelly C, Distler JHW, et al.: Nintedanib in patients with autoimmune disease-related progressive fibrosing interstitial lung diseases: Subgroup analysis of the INBUILD trial. Arthritis Rheumatol 2022; 74: 1039\u201347","DOI":"10.1002\/art.42075"},{"key":"10.3238\/arztebl.m2025.0162_ref10","doi-asserted-by":"crossref","unstructured":"Fischer A, Antoniou KM, Brown KK, et al.: An official European Respiratory Society\/American Thoracic Society research statement: Interstitial pneumonia with autoimmune features. Eur Respir J 2015; 46: 976\u201387","DOI":"10.1183\/13993003.00150-2015"},{"key":"10.3238\/arztebl.m2025.0162_ref11","doi-asserted-by":"crossref","unstructured":"Hoffmann-Vold AM, Maher TM, Philpot EE, et al.: The identification and management of interstitial lung disease in systemic sclerosis: Evidence-based European consensus statements. Lancet Rheumatol 2020; 2: e71\u2013e83","DOI":"10.1016\/S2665-9913(20)30098-9"},{"key":"10.3238\/arztebl.m2025.0162_ref12","doi-asserted-by":"crossref","unstructured":"American Thoracic Society; European Respiratory Society: American Thoracic Society\/ European Respiratory Society International Multidisciplinary Consensus Classification of the Idiopathic Interstitial Pneumonias. This joint statement of the American Thoracic Society (ATS), and the European Respiratory Society (ERS) was adopted by the ATS board of directors, June 2001 and by the ERS Executive Committee, June 2001. Am J Respir Crit Care Med 2002; 165: 277\u2013304","DOI":"10.1164\/ajrccm.165.2.ats01"},{"key":"10.3238\/arztebl.m2025.0162_ref13","doi-asserted-by":"crossref","unstructured":"Travis WD, Costabel U, Hansell DM, et al.: An official American Thoracic Society\/European Respiratory Society statement: Update of the international multidisciplinary classification of the idiopathic interstitial pneumonias. Am J Respir Crit Care Med 2013; 188: 733\u201348","DOI":"10.1164\/rccm.201308-1483ST"},{"key":"10.3238\/arztebl.m2025.0162_ref14","doi-asserted-by":"crossref","unstructured":"Flaherty KR, Wells AU, Cottin V, et al.: Nintedanib in progressive fibrosing interstitial lung diseases. N Engl J Med 2019; 381: 1718\u201327","DOI":"10.1056\/NEJMoa1908681"},{"key":"10.3238\/arztebl.m2025.0162_ref15","doi-asserted-by":"crossref","unstructured":"Wells AU, Flaherty KR, Brown KK, et al.: Nintedanib in patients with progressive fibrosing interstitial lung diseases-subgroup analyses by interstitial lung disease diagnosis in the INBUILD trial: A randomised, double-blind, placebo-controlled, parallel-group trial. Lancet Respir Med 2020; 8: 453\u201360","DOI":"10.1016\/S2213-2600(20)30036-9"},{"key":"10.3238\/arztebl.m2025.0162_ref16","doi-asserted-by":"crossref","unstructured":"Behr J, Bonella F, Frye BC, et al.: Pharmacological treatment of idiopathic pulmonary fibrosis (update) and progressive pulmonary fibroses: S2k guideline of the German respiratory society. Respiration 2024; 103: 782\u2013810","DOI":"10.1159\/000540856"},{"key":"10.3238\/arztebl.m2025.0162_ref17","doi-asserted-by":"crossref","unstructured":"Khanna D, Lin CJF, Furst DE, et al.: Tocilizumab in systemic sclerosis: A randomised, double-blind, placebo-controlled, phase 3 trial. Lancet Respir Med 2020; 8: 963\u201374","DOI":"10.1016\/S2213-2600(20)30318-0"},{"key":"10.3238\/arztebl.m2025.0162_ref18","doi-asserted-by":"crossref","unstructured":"Del Galdo F, Lescoat A, Conaghan PG, et al.: EULAR recommendations for the treatment of systemic sclerosis: 2023 update. Ann Rheum Dis 2025; 84: 29\u201340","DOI":"10.1136\/ard-2024-226430"},{"key":"10.3238\/arztebl.m2025.0162_ref19","doi-asserted-by":"crossref","unstructured":"Raghu G, Montesi SB, Silver RM, et al.: Treatment of systemic sclerosis-associated interstitial lung disease: Evidence-based recommendations. An Official American Thoracic Society Clinical Practice Guideline. Am J Respir Crit Care Med 2024; 209: 137\u201352","DOI":"10.1164\/rccm.202306-1113ST"},{"key":"10.3238\/arztebl.m2025.0162_ref20","doi-asserted-by":"crossref","unstructured":"Stone JH, Merkel PA, Spiera R, et al.: Rituximab versus cyclophosphamide for ANCA-associated vasculitis. N Engl J Med 2010; 363: 221\u201332","DOI":"10.1056\/NEJMoa0909905"},{"key":"10.3238\/arztebl.m2025.0162_ref21","doi-asserted-by":"crossref","unstructured":"Jones RB, Tervaert JW, Hauser T, et al.: Rituximab versus cyclophosphamide in ANCA-associated renal vasculitis. N Engl J Med 2010; 363: 211\u201320","DOI":"10.1056\/NEJMoa0909169"},{"key":"10.3238\/arztebl.m2025.0162_ref22","doi-asserted-by":"crossref","unstructured":"Sircar G, Goswami RP, Sircar D, Ghosh A, Ghosh P: Intravenous cyclophosphamide vs rituximab for the treatment of early diffuse scleroderma lung disease: Open label, randomized, controlled trial. Rheumatology (Oxford) 2018; 57: 2106\u201313","DOI":"10.1093\/rheumatology\/key213"},{"key":"10.3238\/arztebl.m2025.0162_ref23","doi-asserted-by":"crossref","unstructured":"Ebata S, Yoshizaki A, Oba K, et al.: Safety and efficacy of rituximab in systemic sclerosis (DESIRES): A double-blind, investigator-initiated, randomised, placebo-controlled trial. Lancet Rheumatol 2021; 3: e489\u2013e97","DOI":"10.1016\/S2665-9913(21)00107-7"},{"key":"10.3238\/arztebl.m2025.0162_ref24","doi-asserted-by":"crossref","unstructured":"Maher TM, Tudor VA, Saunders P, et al.: Rituximab versus intravenous cyclophosphamide in patients with connective tissue disease-associated interstitial lung disease in the UK (RECITAL): A double-blind, double-dummy, randomised, controlled, phase 2b trial. Lancet Respir Med 2023; 11: 45\u201354","DOI":"10.1016\/S2213-2600(22)00359-9"},{"key":"10.3238\/arztebl.m2025.0162_ref25","doi-asserted-by":"crossref","unstructured":"Distler O, Highland KB, Gahlemann M, et al.: Nintedanib for systemic sclerosis-associated interstitial lung disease. N Engl J Med 2019; 380: 2518\u201328","DOI":"10.1056\/NEJMoa1903076"},{"key":"10.3238\/arztebl.m2025.0162_ref26","doi-asserted-by":"crossref","unstructured":"Buschulte K, Hoffmann-Vold AM, Dobrota RD, H\u00f6ger P, Krause A, Kreuter M: [Treatment of lung fibrosis in systemic rheumatic diseases (new treatment)]. Z Rheumatol 2021; 80: 743\u201354","DOI":"10.1007\/s00393-021-01067-3"},{"key":"10.3238\/arztebl.m2025.0162_ref27","doi-asserted-by":"crossref","unstructured":"Olson A, Hartmann N, Patnaik P, et al.: Estimation of the prevalence of progressive fibrosing interstitial lung diseases: Systematic literature review and data from a physician survey. Adv Ther 2021; 38: 854\u201367","DOI":"10.1007\/s12325-020-01578-6"},{"key":"10.3238\/arztebl.m2025.0162_ref28","doi-asserted-by":"crossref","unstructured":"Kuwana M, Avouac J, Hoffmann-Vold AM, et al.: Development of a multivariable prediction model for progression of systemic sclerosis-associated interstitial lung disease. RMD Open 2024; 10: e004240","DOI":"10.1136\/rmdopen-2024-004240"},{"key":"10.3238\/arztebl.m2025.0162_ref29","doi-asserted-by":"crossref","unstructured":"Hambly N, Farooqi MM, Dvorkin-Gheva A, et al.: Prevalence and characteristics of progressive fibrosing interstitial lung disease in a prospective registry. Eur Respir J 2022; 60: 2102571","DOI":"10.1183\/13993003.02571-2021"},{"key":"10.3238\/arztebl.m2025.0162_ref30","doi-asserted-by":"crossref","unstructured":"Makhzoum JP, Grayson PC, Ponte C, et al.: Pulmonary involvement in primary systemic vasculitides. Rheumatology (Oxford) 2021; 61: 319\u201330","DOI":"10.1093\/rheumatology\/keab325"},{"key":"10.3238\/arztebl.m2025.0162_ref31","doi-asserted-by":"crossref","unstructured":"Hoffmann T, Oelzner P, Franz M, et al.: Assessing the diagnostic value of a potential screening tool for detecting early interstitial lung disease at the onset of inflammatory rheumatic diseases. Arthritis Res Ther 2022; 24: 107","DOI":"10.1186\/s13075-022-02786-x"},{"key":"10.3238\/arztebl.m2025.0162_ref32","doi-asserted-by":"crossref","unstructured":"Tashkin DP, Elashoff R, Clements PJ, et al.: Cyclophosphamide versus placebo in scleroderma lung disease. N Engl J Med 2006; 354: 2655\u201366","DOI":"10.1056\/NEJMoa055120"},{"key":"10.3238\/arztebl.m2025.0162_ref33","doi-asserted-by":"crossref","unstructured":"Hoffmann T, Oelzner P, Busch M, et al.: Organ manifestation and systematic organ screening at the onset of inflammatory rheumatic diseases. Diagnostics 2022; 12: 67","DOI":"10.3390\/diagnostics12010067"},{"key":"10.3238\/arztebl.m2025.0162_ref34","doi-asserted-by":"crossref","unstructured":"Vicente-Rabaneda EF, Bong DA, Casta\u00f1eda S, et al.: Use of ultrasound to diagnose and monitor interstitial lung disease in rheumatic diseases. Clin Rheumatol 2021; 40: 3547\u201364","DOI":"10.1007\/s10067-021-05761-0"},{"key":"10.3238\/arztebl.m2025.0162_ref35","doi-asserted-by":"crossref","unstructured":"Kono M, Nakamura Y, Enomoto N, et al.: Usual interstitial pneumonia preceding collagen vascular disease: A retrospective case control study of patients initially diagnosed with idiopathic pulmonary fibrosis. PLoS One 2014; 9: e94775","DOI":"10.1371\/journal.pone.0094775"},{"key":"10.3238\/arztebl.m2025.0162_ref36","doi-asserted-by":"crossref","unstructured":"Kono M, Nakamura Y, Yoshimura K, et al.: Nonspecific interstitial pneumonia preceding diagnosis of collagen vascular disease. Respir Med 2016; 117: 40\u20137","DOI":"10.1016\/j.rmed.2016.05.030"},{"key":"10.3238\/arztebl.m2025.0162_ref37","doi-asserted-by":"crossref","unstructured":"Simpson FG, Arnold AG, Purvis A, Belfield PW, Muers MF, Cooke NJ: Postal survey of bronchoscopic practice by physicians in the United Kingdom. Thorax 1986; 41: 311\u20137","DOI":"10.1136\/thx.41.4.311"},{"key":"10.3238\/arztebl.m2025.0162_ref38","doi-asserted-by":"crossref","unstructured":"Ahmad M, Livingston DR, Golish JA, Mehta AC, Wiedemann HP: The safety of outpatient transbronchial biopsy. Chest 1986; 90: 403\u20135","DOI":"10.1378\/chest.90.3.403"},{"key":"10.3238\/arztebl.m2025.0162_ref39","doi-asserted-by":"crossref","unstructured":"Pastre J, Khandhar S, Barnett S, et al.: Surgical lung biopsy for interstitial lung disease. Safety and feasibility at a tertiary referral center. Ann Am Thorac Soc 2021; 18: 460\u20137","DOI":"10.1513\/AnnalsATS.202006-759OC"},{"key":"10.3238\/arztebl.m2025.0162_ref40","doi-asserted-by":"crossref","unstructured":"Kalverda KA, Ninaber MK, Wijmans L, et al.: Transbronchial cryobiopsy followed by as-needed surgical lung biopsy versus immediate surgical lung biopsy for diagnosing interstitial lung disease (the COLD study): A randomised controlled trial. Lancet Respir Med 2024; 12: 513\u201322","DOI":"10.1016\/S2213-2600(24)00074-2"},{"key":"10.3238\/arztebl.m2025.0162_ref41","unstructured":"Robert Koch-Institut: Impfkalender der STIKO. 2024. www.rki.de\/DE\/Content\/Kommissionen\/STIKO\/Empfehlungen\/Aktuelles\/Impfkalender.html (last accessed on 8 October 2024)."},{"key":"10.3238\/arztebl.m2025.0162_ref42","doi-asserted-by":"crossref","unstructured":"Dowman LM, McDonald CF, Hill CJ, et al.: The evidence of benefits of exercise training in interstitial lung disease: A randomised controlled trial. Thorax 2017; 72: 610\u20139","DOI":"10.1136\/thoraxjnl-2016-208638"},{"key":"10.3238\/arztebl.m2025.0162_ref43","doi-asserted-by":"crossref","unstructured":"Izumi Y, Akazawa M, Akeda Y, et al.: The 23-valent pneumococcal polysaccharide vaccine in patients with rheumatoid arthritis: A double-blinded, randomized, placebo-controlled trial. Arthritis Res Ther 2017; 19: 15","DOI":"10.1186\/s13075-016-1207-7"},{"key":"10.3238\/arztebl.m2025.0162_ref44","unstructured":"Bundesausschuss G: Beschluss des Gemeinsamen Bundesausschusses \u00fcber eine \u00c4nderung der Schutzimpfungs-Richtlinie: Umsetzung \u201eImpfempfehlung gegen Erkrankungen durch Respiratorische Synzytial-Viren f\u00fcr Personen ab dem Alter von 75 Jahren\u201c sowie Anpassung der Anlage 2. www.g-ba.de\/beschluesse\/6787\/ (last accessed on 8 October 2024)."},{"key":"10.3238\/arztebl.m2025.0162_ref45","unstructured":"Haidl P, Jany B, Geiseler J, et al.: [Guideline for long-term oxygen therapy\u2014S2k-guideline published by the German Respiratory Society]. Pneumologie 2020; 74: 813\u201341."},{"key":"10.3238\/arztebl.m2025.0162_ref46","doi-asserted-by":"crossref","unstructured":"Dowman L, Hill CJ, May A, Holland AE: Pulmonary rehabilitation for interstitial lung disease. Cochrane Database Syst Rev 2021; 2: Cd006322","DOI":"10.1002\/14651858.CD006322.pub4"},{"key":"10.3238\/arztebl.m2025.0162_ref47","doi-asserted-by":"crossref","unstructured":"Kreuter M, Bendstrup E, Russell AM, et al.: Palliative care in interstitial lung disease: Living well. Lancet Respir Med 2017; 5: 968\u201380","DOI":"10.1016\/S2213-2600(17)30383-1"},{"key":"10.3238\/arztebl.m2025.0162_ref48","doi-asserted-by":"crossref","unstructured":"Yamasaki Y, Yamada H, Yamasaki M, et al.: Intravenous cyclophosphamide therapy for progressive interstitial pneumonia in patients with polymyositis\/dermatomyositis. Rheumatology (Oxford) 2007; 46: 124\u201330","DOI":"10.1093\/rheumatology\/kel112"},{"key":"10.3238\/arztebl.m2025.0162_ref49","doi-asserted-by":"crossref","unstructured":"Hyldgaard C, Hilberg O, Pedersen AB, et al.: A population-based cohort study of rheumatoid arthritis-associated interstitial lung disease: Comorbidity and mortality. Ann Rheum Dis 2017; 76: 1700\u201306","DOI":"10.1136\/annrheumdis-2017-211138"},{"key":"10.3238\/arztebl.m2025.0162_ref50","doi-asserted-by":"crossref","unstructured":"Nikpour M, Baron M: Mortality in systemic sclerosis: Lessons learned from population-based and observational cohort studies. Curr Opin Rheumatol 2014; 26: 131\u20137","DOI":"10.1097\/BOR.0000000000000027"},{"key":"10.3238\/arztebl.m2025.0162_ref51","doi-asserted-by":"crossref","unstructured":"Huang H, Xie W, Geng Y, Fan Y, Zhang Z: Mortality in patients with primary Sj\u00f6gren\u2018s syndrome: a systematic review and meta-analysis. Rheumatology (Oxford) 2021; 60: 4029\u201338","DOI":"10.1093\/rheumatology\/keab364"},{"key":"10.3238\/arztebl.m2025.0162_ref52","doi-asserted-by":"crossref","unstructured":"Johnson C, Pinal-Fernandez I, Parikh R, et al.: Assessment of mortality in autoimmune myositis with and without associated interstitial lung disease. Lung 2016; 194: 733\u20137","DOI":"10.1007\/s00408-016-9896-x"},{"key":"10.3238\/arztebl.m2025.0162_ref53","doi-asserted-by":"crossref","unstructured":"Zhou P, Ma J, Wang G: Impact of interstitial lung disease on mortality in ANCA-associated vasculitis: A systematic literature review and meta-analysis. Chron Respir Dis 2021; 18: 1479973121994562","DOI":"10.1177\/1479973121994562"},{"key":"10.3238\/arztebl.m2025.0162_ref54","doi-asserted-by":"crossref","unstructured":"Pugashetti JV, Adegunsoye A, Wu Z, et al.: Validation of proposed criteria for progressive pulmonary fibrosis. Am J Respir Crit Care Med 2023; 207: 69\u201376","DOI":"10.1164\/rccm.202201-0124OC"},{"key":"10.3238\/arztebl.m2025.0162_ref55","doi-asserted-by":"crossref","unstructured":"Albrecht K, Binder S, Minden K, et al.: [Systematic review to estimate the prevalence of inflammatory rheumatic diseases in Germany. German version]. Z Rheumatol 2023; 82: 727\u201338","DOI":"10.1007\/s00393-022-01305-2"},{"key":"10.3238\/arztebl.m2025.0162_ref56","doi-asserted-by":"crossref","unstructured":"Provan SA, Ahlfors F, Bakland G, et al.: A validation of register-derived diagnoses of interstitial lung disease in patients with inflammatory arthritis: Data from the NOR-DMARD study. Scand J Rheumatol 2024; 53: 173\u20139","DOI":"10.1080\/03009742.2024.2306716"},{"key":"10.3238\/arztebl.m2025.0162_ref57","doi-asserted-by":"crossref","unstructured":"Provan SA, Ljung L, Kristianslund EK, et al.: Interstitial lung disease in patients with rheumatoid arthritis or psoriatic arthritis initiating biologics and controls: Data from 5 nordic registries. J Rheumatol 2024; 51: 1111\u20138","DOI":"10.3899\/jrheum.2024-0252"},{"key":"10.3238\/arztebl.m2025.0162_ref58","doi-asserted-by":"crossref","unstructured":"Dabit JY, Valenzuela-Almada MO, Vallejo-Ramos S, et al.: Epidemiology of antiphospholipid syndrome in the general population. Curr Rheumatol Rep 2022; 23: 85","DOI":"10.1007\/s11926-021-01038-2"},{"key":"10.3238\/arztebl.m2025.0162_ref59","doi-asserted-by":"crossref","unstructured":"Wallace ZS, Miles G, Smolkina E, et al.: Incidence, prevalence and mortality of IgG4\u2013related disease in the USA: A claims-based analysis of commercially insured adults. Ann Rheum Dis 2023; 82: 957\u201362","DOI":"10.1136\/ard-2023-223950"},{"key":"10.3238\/arztebl.m2025.0162_ref60","doi-asserted-by":"crossref","unstructured":"Hansen DL, M\u00f6ller S, Andersen K, et al.: Increasing incidence and prevalence of acquired hemolytic anemias in Denmark, 1980\u20132016. Clin Epidemiol 2020; 12: 497\u2013508","DOI":"10.2147\/CLEP.S250250"},{"key":"10.3238\/arztebl.m2025.0162_ref61","doi-asserted-by":"crossref","unstructured":"Terrell DR, Beebe LA, Neas BR, et al.: Prevalence of primary immune thrombocytopenia in Oklahoma. Am J Hematol 2012; 87: 848\u201352","DOI":"10.1002\/ajh.23262"},{"key":"10.3238\/arztebl.m2025.0162_ref62","doi-asserted-by":"crossref","unstructured":"Mobasseri M, Shirmohammadi M, Amiri T, Vahed N, Hosseini Fard H, Ghojazadeh M: Prevalence and incidence of type 1 diabetes in the world: A systematic review and meta-analysis. Health Promot Perspect 2020; 10: 98\u2013115","DOI":"10.34172\/hpp.2020.18"},{"key":"10.3238\/arztebl.m2025.0162_ref63","doi-asserted-by":"crossref","unstructured":"McLeod DSA, Cooper DS: The incidence and prevalence of thyroid autoimmunity. Endocrine 2012; 42: 252\u201365","DOI":"10.1007\/s12020-012-9703-2"},{"key":"10.3238\/arztebl.m2025.0162_ref64","doi-asserted-by":"crossref","unstructured":"Molodecky NA, Soon IS, Rabi DM, et al.: Increasing incidence and prevalence of the inflammatory bowel diseases with time, based on systematic review. Gastroenterology 2012; 142: 46\u201354. e42; quiz e30","DOI":"10.1053\/j.gastro.2011.10.001"},{"key":"10.3238\/arztebl.m2025.0162_ref65","doi-asserted-by":"crossref","unstructured":"Strassburg CP, Beckebaum S, Geier A, et al.: Leitlinienreport zur S2k Leitlinie Autoimmune Lebererkrankungen. Z Gastroenterol 2017; 55: 1135\u2013226","DOI":"10.1055\/s-0043-120123"},{"key":"10.3238\/arztebl.m2025.0162_ref66","unstructured":"Hemmer B: Diagnose und Therapie der Multiplen Sklerose, Neuromyelitis-optica-Spektrum-Erkrankungen und MOG-IgG-assoziierten Erkrankungen, S2k-Leitlinie. Deutsche Gesellschaft f\u00fcr Neurologie (eds.): Leitlinien f\u00fcr Diagnostik und Therapie in der Neurologie. 2023."},{"key":"10.3238\/arztebl.m2025.0162_ref67","unstructured":"Behr J, G\u00fcnther A, Bonella F, et al.: [German guideline for idiopathic pulmonary fibrosis]. Pneumologie 2020; 74: 263\u201393."},{"key":"10.3238\/arztebl.m2025.0162_ref68","doi-asserted-by":"crossref","unstructured":"Pemmasani G, Loftus EV, Tremaine WJ: Prevalence of pulmonary diseases in association with inflammatory bowel disease. Dig Dis Sci 2022; 67: 5187\u201394","DOI":"10.1007\/s10620-022-07385-z"},{"key":"10.3238\/arztebl.m2025.0162_ref69","unstructured":"Bruni C, Tashkin DP, Steen V, et al.: Intravenous versus oral cyclophosphamide for lung and\/or skin fibrosis in systemic sclerosis: An indirect comparison from EUSTAR and randomised controlled trials. Clin Exp Rheumatol 2020; 38 Suppl 125: 161\u20138."},{"key":"10.3238\/arztebl.m2025.0162_ref70","doi-asserted-by":"crossref","unstructured":"Coultas DB, Zumwalt RE, Black WC, Sobonya RE: The epidemiology of interstitial lung diseases. Am J Respir Crit Care Med 1994; 150: 967\u201372","DOI":"10.1164\/ajrccm.150.4.7921471"},{"key":"10.3238\/arztebl.m2025.0162_ref71","doi-asserted-by":"crossref","unstructured":"Olson AL, Patnaik P, Hartmann N, et al.: Prevalence and incidence of chronic fibrosing interstitial lung diseases with a progressive phenotype in the United States estimated in a large claims database analysis. Adv Ther 2021; 38: 4100\u201314","DOI":"10.1007\/s12325-021-01786-8"},{"key":"10.3238\/arztebl.m2025.0162_ref72","doi-asserted-by":"crossref","unstructured":"Harbord M, Annese V, Vavricka SR, et al.: The first European evidence-based consensus on extra-intestinal manifestations in inflammatory bowel disease. J Crohns Colitis 2016; 10: 239\u201354","DOI":"10.1093\/ecco-jcc\/jjv213"},{"key":"10.3238\/arztebl.m2025.0162_ref73","doi-asserted-by":"crossref","unstructured":"Moda M, Suga M, Kasai S, et al.: Incidence, characteristics, clinical course, and risk factors of ulcerative colitis-related lung diseases. Chest 2022; 162: 1310\u201323","DOI":"10.1016\/j.chest.2022.05.037"},{"key":"10.3238\/arztebl.m2025.0162_ref74","doi-asserted-by":"crossref","unstructured":"Wang HF, Wang YY, Li ZY, He PJ, Liu S, Li QS: The prevalence and risk factors of rheumatoid arthritis-associated interstitial lung disease: A systematic review and meta-analysis. Ann Med 2024; 56: 2332406","DOI":"10.1080\/07853890.2024.2332406"},{"key":"10.3238\/arztebl.m2025.0162_ref75","doi-asserted-by":"crossref","unstructured":"Walsh SL, Wells AU, Desai SR, et al.: Multicentre evaluation of multidisciplinary team meeting agreement on diagnosis in diffuse parenchymal lung disease: A case-cohort study. Lancet Respir Med 2016; 4: 557\u201365","DOI":"10.1016\/S2213-2600(16)30033-9"},{"key":"10.3238\/arztebl.m2025.0162_ref76","doi-asserted-by":"crossref","unstructured":"Hoffmann T, Oelzner P, Teichgr\u00e4ber U, et al.: Diagnosing lung involvement in inflammatory rheumatic diseases\u2014where do we currently stand? Front Med (Lausanne) 2022; 9: 1101448","DOI":"10.3389\/fmed.2022.1101448"},{"key":"10.3238\/arztebl.m2025.0162_ref77","doi-asserted-by":"crossref","unstructured":"Hoffmann T, Teichgr\u00e4ber U, F\u00f6rster M, et al.: Correlation of high-resolution computed tomography and immunological bronchoalveolar lavage in interstitial lung disease at the onset of inflammatory rheumatic diseases: Implications for diagnosis and therapeutic strategies. Arthritis Res Ther 2024; 26: 142","DOI":"10.1186\/s13075-024-03371-0"},{"key":"10.3238\/arztebl.m2025.0162_ref78","doi-asserted-by":"crossref","unstructured":"Meyer KC, Raghu G, Baughman RP, et al.: An official American thoracic society clinical practice guideline: The clinical utility of bronchoalveolar lavage cellular analysis in interstitial lung disease. Am J Respir Crit Care Med 2012; 185: 1004\u201314","DOI":"10.1164\/rccm.201202-0320ST"},{"key":"10.3238\/arztebl.m2025.0162_ref79","doi-asserted-by":"crossref","unstructured":"Meyer KC, Raghu G: Bronchoalveolar lavage for the evaluation of interstitial lung disease: Is it clinically useful? Eur Respir J 2011; 38: 761\u20139","DOI":"10.1183\/09031936.00069509"},{"key":"10.3238\/arztebl.m2025.0162_ref80","doi-asserted-by":"crossref","unstructured":"Adams TN, Batra K, Silhan L, et al.: Utility of bronchoalveolar lavage and transbronchial biopsy in patients with interstitial lung disease. Lung 2020; 198: 803\u201310","DOI":"10.1007\/s00408-020-00389-4"},{"key":"10.3238\/arztebl.m2025.0162_ref81","doi-asserted-by":"crossref","unstructured":"Kayatta MO, Ahmed S, Hammel JA, et al.: Surgical biopsy of suspected interstitial lung disease is superior to radiographic diagnosis. Ann Thorac Surg 2013; 96: 399\u2013401","DOI":"10.1016\/j.athoracsur.2013.04.065"},{"key":"10.3238\/arztebl.m2025.0162_ref82","doi-asserted-by":"crossref","unstructured":"Tashkin DP, Roth MD, Clements PJ, et al.: Mycophenolate mofetil versus oral cyclophosphamide in scleroderma-related interstitial lung disease (SLS II): A randomised controlled, double-blind, parallel group trial. Lancet Respir Med 2016; 4: 708\u201319","DOI":"10.1016\/S2213-2600(16)30152-7"},{"key":"10.3238\/arztebl.m2025.0162_ref83","doi-asserted-by":"crossref","unstructured":"Sullivan KM, Goldmuntz EA, Keyes-Elstein L, et al.: Myeloablative autologous stem-cell transplantation for severe scleroderma. N Engl J Med 2018; 378: 35\u201347","DOI":"10.1056\/NEJMc1801275"},{"key":"10.3238\/arztebl.m2025.0162_ref84","doi-asserted-by":"crossref","unstructured":"M\u00fcller F, Taubmann J, Bucci L, et al.: CD19 CAR T-cell therapy in autoimmune disease\u2014a case series with follow-up. N Engl J Med 2024; 390: 687\u2013700","DOI":"10.1056\/NEJMoa2308917"},{"key":"10.3238\/arztebl.m2025.0162_ref85","doi-asserted-by":"crossref","unstructured":"Kiely P, Busby AD, Nikiphorou E, et al.: Is incident rheumatoid arthritis interstitial lung disease associated with methotrexate treatment? Results from a multivariate analysis in the ERAS and ERAN inception cohorts. BMJ Open 2019; 9: e028466","DOI":"10.1136\/bmjopen-2018-028466"},{"key":"10.3238\/arztebl.m2025.0162_ref86","doi-asserted-by":"crossref","unstructured":"Juge PA, Lee JS, Lau J, et al.: Methotrexate and rheumatoid arthritis associated interstitial lung disease. Eur Respir J 2021; 57: 2000337","DOI":"10.1183\/13993003.00337-2020"},{"key":"10.3238\/arztebl.m2025.0162_ref87","doi-asserted-by":"crossref","unstructured":"Baker MC, Liu Y, Lu R, Lin J, Melehani J, Robinson WH: Incidence of interstitial lung disease in patients with rheumatoid arthritis treated with biologic and targeted synthetic disease\u2014modifying antirheumatic drugs. JAMA Netw Open 2023; 6: e233640","DOI":"10.1001\/jamanetworkopen.2023.3640"},{"key":"10.3238\/arztebl.m2025.0162_ref88","doi-asserted-by":"crossref","unstructured":"Behr J, Prasse A, Kreuter M, et al.: Pirfenidone in patients with progressive fibrotic interstitial lung diseases other than idiopathic pulmonary fibrosis (RELIEF): A double-blind, randomised, placebo-controlled, phase 2b trial. Lancet Respir Med 2021; 9: 476\u201386","DOI":"10.1016\/S2213-2600(20)30554-3"},{"key":"10.3238\/arztebl.m2025.0162_ref89","doi-asserted-by":"crossref","unstructured":"Solomon JJ, Danoff SK, Woodhead FA, et al.: Safety, tolerability, and efficacy of pirfenidone in patients with rheumatoid arthritis-associated interstitial lung disease: A randomised, double-blind, placebo-controlled, phase 2 study. Lancet Respir Med 2023; 11: 87\u201396","DOI":"10.1016\/j.chest.2021.12.293"}],"container-title":["Deutsches \u00c4rzteblatt international"],"original-title":[],"link":[{"URL":"https:\/\/www.aerzteblatt.de\/10.3238\/arztebl.m2025.0162","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2025,11,20]],"date-time":"2025-11-20T13:09:55Z","timestamp":1763644195000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.aerzteblatt.de\/10.3238\/arztebl.m2025.0162"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2025,11,28]]},"references-count":89,"URL":"https:\/\/doi.org\/10.3238\/arztebl.m2025.0162","relation":{},"ISSN":["1866-0452"],"issn-type":[{"value":"1866-0452","type":"electronic"}],"subject":[],"published":{"date-parts":[[2025,11,28]]}}}